Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy

Purpose: To evaluate the effect of orbital steroid injections in patients with active thyroid ophthalmopathy resistant to or dependent on systemic steroids, or with complications related to systemic steroid use. Methods: This prospective non-comparative case series includes 31 eyes of 17 patie...

Full description

Bibliographic Details
Main Authors: Abbas Bagheri, Mohammad Abbaszadeh, Shahin Yazdani
Format: Article
Language:English
Published: Knowledge E 2020-02-01
Series:Journal of Ophthalmic & Vision Research
Subjects:
Online Access:https://doi.org/10.18502/jovr.v15i1.5948
_version_ 1811332677019631616
author Abbas Bagheri
Mohammad Abbaszadeh
Shahin Yazdani
author_facet Abbas Bagheri
Mohammad Abbaszadeh
Shahin Yazdani
author_sort Abbas Bagheri
collection DOAJ
description Purpose: To evaluate the effect of orbital steroid injections in patients with active thyroid ophthalmopathy resistant to or dependent on systemic steroids, or with complications related to systemic steroid use. Methods: This prospective non-comparative case series includes 31 eyes of 17 patients with active thyroid ophthalmopathy and clinical activity score (CAS) of 3 or more, without compressive optic neuropathy or overt exposure keratopathy. All subjects had a history of previous systemic steroid use (with steroid resistance or dependence) or had developed complications related to steroids. A combination of steroids including triamcinolone acetonide 20 mg and dexamethasone 4 mg was injected in the upper and lower retroseptal orbital spaces three or four times at one-month intervals. The patients were examined periodically after each injection and at least three months after the last injection. Results: Mean pre-injection CAS was 5.2 ± 1.3 which was improved to 1.6 ± 1 after the fourth injection (P < 0.001). Upper and lower lid retraction improved in 100% and 68.2% of the affected eyes, respectively. Strabismus completely resolved in one of five affected patients and the most significant improvement was observed in supraduction. Mean improvement in exophthalmos was 1.2 ± 1.1 mm. Visual acuity did not significantly change after the injections. Eyelid ecchymosis and/or subconjunctival hemorrhage was observed in 7.1% and intraocular pressure rise occurred in 8.8% of eyes. Conclusion: Orbital steroid injections can be used for the treatment of active thyroid ophthalmopathy when the patient is resistant to or dependent on systemic steroids or has developed complications of systemic steroids.
first_indexed 2024-04-13T16:40:33Z
format Article
id doaj.art-ffd4e4032a12468ba4eb75d01e4b2ac7
institution Directory Open Access Journal
issn 2008-322X
language English
last_indexed 2024-04-13T16:40:33Z
publishDate 2020-02-01
publisher Knowledge E
record_format Article
series Journal of Ophthalmic & Vision Research
spelling doaj.art-ffd4e4032a12468ba4eb75d01e4b2ac72022-12-22T02:39:16ZengKnowledge EJournal of Ophthalmic & Vision Research2008-322X2020-02-0115697710.18502/jovr.v15i1.5948Intraorbital Steroid Injection for Active Thyroid OphthalmopathyAbbas Bagheri0Mohammad Abbaszadeh1Shahin Yazdani2Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranOphthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranOphthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranPurpose: To evaluate the effect of orbital steroid injections in patients with active thyroid ophthalmopathy resistant to or dependent on systemic steroids, or with complications related to systemic steroid use. Methods: This prospective non-comparative case series includes 31 eyes of 17 patients with active thyroid ophthalmopathy and clinical activity score (CAS) of 3 or more, without compressive optic neuropathy or overt exposure keratopathy. All subjects had a history of previous systemic steroid use (with steroid resistance or dependence) or had developed complications related to steroids. A combination of steroids including triamcinolone acetonide 20 mg and dexamethasone 4 mg was injected in the upper and lower retroseptal orbital spaces three or four times at one-month intervals. The patients were examined periodically after each injection and at least three months after the last injection. Results: Mean pre-injection CAS was 5.2 ± 1.3 which was improved to 1.6 ± 1 after the fourth injection (P < 0.001). Upper and lower lid retraction improved in 100% and 68.2% of the affected eyes, respectively. Strabismus completely resolved in one of five affected patients and the most significant improvement was observed in supraduction. Mean improvement in exophthalmos was 1.2 ± 1.1 mm. Visual acuity did not significantly change after the injections. Eyelid ecchymosis and/or subconjunctival hemorrhage was observed in 7.1% and intraocular pressure rise occurred in 8.8% of eyes. Conclusion: Orbital steroid injections can be used for the treatment of active thyroid ophthalmopathy when the patient is resistant to or dependent on systemic steroids or has developed complications of systemic steroids.https://doi.org/10.18502/jovr.v15i1.5948graveslid retractionorbital inflammationproptosissteroid injection
spellingShingle Abbas Bagheri
Mohammad Abbaszadeh
Shahin Yazdani
Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
Journal of Ophthalmic & Vision Research
graves
lid retraction
orbital inflammation
proptosis
steroid injection
title Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
title_full Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
title_fullStr Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
title_full_unstemmed Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
title_short Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
title_sort intraorbital steroid injection for active thyroid ophthalmopathy
topic graves
lid retraction
orbital inflammation
proptosis
steroid injection
url https://doi.org/10.18502/jovr.v15i1.5948
work_keys_str_mv AT abbasbagheri intraorbitalsteroidinjectionforactivethyroidophthalmopathy
AT mohammadabbaszadeh intraorbitalsteroidinjectionforactivethyroidophthalmopathy
AT shahinyazdani intraorbitalsteroidinjectionforactivethyroidophthalmopathy